PatrickKevinRevilleMDMPH(He/Him)

Hematologic Oncology

Assistant Professor, Department of Leukemia University of Texas MD Anderson Cancer Center

Dr. Reville is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Patrick Reville is a dedicated physician specializing in the care and treatment of patients with hematologic malignancies and other blood disorders. My passion lies in fostering shared decision-making and promoting open, effective communication to empower patients and provide compassionate, personalized care.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
Baylor College of MedicineResidency, Internal Medicine, 2017 - 2019
University of Wisconsin School of Medicine & Public HealthClass of 2017, MD
The Ohio State University MPH, Public Health , 2010 - 2011
The Ohio State UniversityBS, Microbiology, 2005 - 2009

Waun Ki Hong Award for Achievement in Basic Science Research University of Texas MD Anderson Cancer Center, 2022
Journal of Clinical Oncology Young Investigator Award Conquer Cancer Foundation, 2022
Lymphoma Scientist Research Mentoring Program (LSRMP) – Translational Scholar Lymphoma Research Foundation, 2022
Abstract Achievement Award ASH, 2021
Dylan Cappel Memorial Scholarship Grantee University of Wisconsin School of Medicine and Public Health, 2017
Research Honors Distinction University of Wisconsin School of Medicine and Public Health, 2017
Shapiro Research Fellowship University of Wisconsin School of Medicine and Public Health, 2014
Join now to see all

PubMed

Journal Articles

ANNA-1 Paraneoplastic Encephalomyelitis Presenting as Rapidly Progressing Dementia in a Man With Undiagnosed Small Cell Lung Cancer
Reville PK, Steingraeber C, The American Journal of Psychiatry Residents' Journal

Addition of Venetoclax to Intensive Chemotherapy Yields Durable Responses in Younger Patients With High-Risk AMLFebruary 25th, 2023
“Eye-Popping” Results From Adding Venetoclax to CLIA in Newly Diagnosed AMLJanuary 5th, 2023
Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIADecember 16th, 2022
Join now to see all

Inflammatory Signatures to Improve AML Risk Prognostication and Venetoclax Treatment PredictionNational Cancer Institute2024–2025
CD38 as a Targetable Antigen in Large B Cell Lymphoma Combined with CD19 CAR T CellsLymphoma Research Foundation2022–2024
CD38 as a Targetable Antigen in Large B Cell Lymphoma (LBCL) to improve the efficacy CD19 Directed Chimeric Antigen Receptor T (CAR T) Cell Therapy and Mitigate CD19 Negative RelapseConquer Cancer Foundation2022–2023
Defining Biomarkers and Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Large B-cell LymphomaNational Cancer Institute2021–2023
NIH T32 Training Grant, Ruth L. Kirschstein National Research Service AwardsNIH2020–2022

Google Scholar Pagehttps://scholar.google.com/citations?user=onD3Vd8AAAAJ&hl=en
Faculty profile https://faculty.mdanderson.org/profiles/patrick_reville.html